Literaturreferenzen des Artikels "Erworbene hämolytische Anämien"

 Druckversion

Autor/en: A. Salama
Letzte Änderung: 11.11.2003

• Ahrens N, Heymann G, Meyer 0, Kiesewetter H, Salama A.
  Results of Treatment with Rituximab (Anti-CD20) in Three Patients with Autoimmune Hemolytic Anemia and/or Immune Thrombocytopenia and a Concise Review of Reported Cases.
  Infus Ther Transfus Med 2002;29:277-281.




• Astori C, Bonfichi M, Pagnucco G, Bernasconi P, Lazzarino M, Orlandi E, Bernasconi C.
  Treatment with recombinant human erythropoietin (rHuEpo) in a patient with paroxysmal nocturnal haemoglobinuria: evaluation of membrane proteins CD55 and CD59 with cytofluorometric assay.
  Br J Haematol 1997;97(3): 586-588.




• Beauregard P, Blajchman MA.
  Hemolytic and Pseudo-Hemolytic Transfusion Reactions: An Overview of the Hemolytic Transfusion Reactions and the Clinical Conditions That Mimic Them.
  Transfusion Medicine Reviews 1994;VIII/3:184-199.




• Bessler M, Masin PJ, Hillmen P, Miyata T, Yamada N, Takeda J, Luzzatto L, Kinoshita T.
  Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.
  The EMBO Journal 1994;13:110-117.




• Beutler E.
  Hemolytic anemia due to infections with microorganisms.
  Fifth edition, Williams Hematology 1995;63:674-676.




• Beutler E.
  Hemolytic anemia due to chemical and physical agents.
  Fifth edition, Williams Hematology 1995;62:670-673.




• Bowman JM.
  Treatment Options for the Fetus With Alloimmune Hemolytic Disease.
  Transfusion Medicine Reviews 1990;IV/3:191-207.




• Buchanan GR, Boxer LA, Nathan DG.
  The acute and transient nature of idiopathic immune hemolytic anemia in childhood.
  J Pediatrics 1976;88:780-783.




• Chemnitz J, Draube A, Scheid C, et al.
  Sucessful Treatment of Severe Thrombotic Thrombocytopenic Purpura With the Monoclonal Antibody Rituximab.
  Am J Hematology 2002;71:105-180.




• Dabrow MB, Gabuzda TG.
  Nonimmune Hemolysis and Toxic Methemoglobinemia.
  Comprehensive Toxicology.
  Elsevier Science Ltd., United Kingdom, 1997;4:55-72.




• Dacie JV, Worlledge SM.
  Auto-Immune Hemolytic Anemias.
  Progr Hematol 1969;6:82-120.




• Engelfriet CP, Overbeeke MAM, von dem Borne AEGKr.
  Autoimmune Hemolytic Anemia.
  Seminars in Hematology 1992;29:3-12.




• Erslev AJ.
  Traumatic cardiac hemolytic anemia. Fifth edition.
  Williams Hematology 1995;59:663-665.




• Erslev AJ.
  March hemoglobinuria and sports anemia. Fifth edition.
  Williams Hematology 1995;61:669-670.




• Garratty G.
  Immunobiology of Transfusion Medicine.
  Marcel Dekker, Inc., New York, 1994.




• Gehrs BC, Friedberg RC.
  Autoimmune Hemolytic Anemia.
  Am J Hematology 2002;69:258-271.




• George JN.
  How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
  Blood 2000;96:1223-1229.




• Göttsche B, Salama A, Mueller-Eckhardt C.
  Donath-Landsteiner autoimmune hemolytic anemia in children. A study of 22 cases.
  Vox Sang 1990;58:281-286.




• Gordjani N, Kretschmer V, Töllner U, Rieger C.
  Foudroyant verlaufende Autoimmunhämolyse vom Kältetyp mit ausgeprägter Vermehrung von monothermischen Kälteagglutininen: Erfolgreiche Therapie mit Membranplasmapherese.
  Monatsschr Kinderheilkd 1990;138:454-456.




• Habibi B, Homberg J-C, Schaison G, Salmon C.
  Autoimmune Hemolytic Anemia in Children.
  Am J Medicine 1974;56:61-69.




• Hadnagy CS.
  Agewise distribution of idiopathic cold agglutinin disease.
  Z Gerontol 1993;24:199-201.




• Indik ZK et al.
  The molecular dissection for Fcg RII receptor mediated phagocytosis.
  Blood 1995;86:4389.




• Kelton JG.
  Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: will recent insight into pathogenesis translate into better treatment?
  Transfusion 2002;42:388-392.




• Kokame K, Matsumoto M, Soejima K et al.
  Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.
  PNAS 2002;99:11902-11907.




• Lankford KV, Hillyer CD.
  Thrombotic Thrombocytopenic Purpura: New Insights in Disease Pathogenesis and Therapy.
  Transf Med Reviews 2000;14:244-257.




• Liszewski MK, Farries TC, Lublin CM, Rooney IA, Atkinson JP.
  Control of the Complement System.
  Advances in Immunology 1996;61:201-283.




• Luban NLC.
  Review of Neonatal Red Cell Transfusion Practices.
  Blood Transfusion 1994;8:148-153.




• Mack P, Freedman J.
  Autoimmune Hemolytic Anemia: A History.
  Transf Med Reviews 2000;14:223-233.




• Martinez J.
  Microangiopathic hemolytic anemia.
  Fifth edition, Williams Hematology 1995;60:665-668.




• Meletis J, Terpos, E
  Recent insights into the pathophysiology of paroxysmal nocturnal hemoglobinuria.
  Med Sci Monit 2003;9(7):RA161-172.




• Meyer O, Hackstein H, Hoppe B, Göbel F-J, Bein G, Salama A.
  Fatal immune haemolysis due to a degradation product of ceftriaxone.
  Br J Haematology 1999;105:1-4.




• Moake JL.
  Thrombotic Micorangiopathies.
  N Engl J Med 2002;347:589-600.




• Mollision PL, Engelfriet CP, Contreras M.
  Blood Transfusion in Clinical Medicine.
  Tenth edition, Blackwell Science Ltd., 1997




• Richards A, Goodship JA, Goodship THJ.
  The genetics and pathogenesis of haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura.
  Curr Opin Nephrol Hypertens 2002;11:431-435.




• Salama A, Ahrens N, Kiesewetter H.
  Serological and Clinical Aspects of Autoimmune Hemolytic Anemias.
  Infus Ther Transfus Med 2002;29:206-217.




• Salama A, Mueller-Eckhardt C.
  Immune-Mediated Blood Cell Dyscrasias Related to Drugs.
  Seminars in Hematology 1992;29:54-63.




• Salama A, Mueller-Eckhardt C.
  Autoimmune haemolytic anaemia in childhood associated with non-complement binding IgM autoantibodies.
  Brit J Haemat 1987;65:67-71.




• Salama A, Mueller-Eckhardt C.
  The role of metabolite-specific antibodies nomifensine-dependent immune hemolytic anemia.
  New Engl J Med 1985;313:469-474.




• Salama A, Mueller-Eckhardt C.
  Delayed hemolytic transfusion reactions. Evidence for complement activation involving allogeneic and autologous red cells.
  Transfusion 1984;24:188-193.




• Salama A, Bhakdi S, Mueller-Eckhardt C, Kayser W.
  Deposition of the terminal C5b-9 complement complex on erythrocytes by human red cell autoantibodies.
  Brit J Haemat 1983;55:161-160.




• Socieé G. Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, Heudier P, Rochant H, Cahn JY, Gluckman E.
  Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors.
  The Lancet 1996;348:573-577.




• Sokol RJ, Hewitt S, Stamps,BK, Hitchen PA.
  Autoimmune Haemolysis in Childhood and Adolescence.
  Acta haemat 1984;72:245-257.




• Schreiber AD, Frank MM.
  Role of antibody and complement in the immune clearance and destruction of erythrocytes . I. In vivo effects of IgG and IgM complement-fixing sites.
  J Clin Invest 1972;51:575.




• Terada K, Tanaka H, Mori et al.
  Hemolytic Anemia Associated with Cold Agglutinin During Chickenpox and a Review of the Literature.
  J Ped Hematology/Oncology 1998;20:194-151.




• Zecca M, Nobili B, Ramenghi U, Perrotta S.
  Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.
  Blood 2003;101:3857-3861.




• Zuelzer WW, Mastrangelo R, Stulberg CS.
  Autoimmune Hemolytic Anemia. Natural History and Viral-Immunologic Interactions in Childhood.
  Am J Medicine 1970;49:80-93.

Herausgeber: Prof. Dr. H. Link
Herausgeberbeirat: Prof. Dr. P. Albers, Prof. Dr. R. Andreesen, Priv.-Doz. Dr. A. Böhme, Prof. Dr. C. Bokemeyer, Prof. Dr. U. Creutzig, Prof. Dr. G. Ehninger, Prof. Dr. M. Freund, Prof. Dr. C. Garbe, Dr. N. Gökbuget, Prof. Dr. M. Hallek, Prof. Dr. J.T. Hartmann, Prof. Dr. R. Hehlmann, Prof. emerit. Dr. H. Heimpel, Prof. Dr. A. Hochhaus, Prof. Dr. K. Höffken, Dr. G. Hübner, Prof. Dr. Th. Junginger, Priv.-Doz. Dr. U. Kaiser, Priv.-Doz. Dr. R. Kath, Prof. Dr. C.-H. Köhne, Dr. R. Mahlberg, Prof. Dr. A. Matzdorff, Prof. Dr. R.-P. Müller, Prof. Dr. J. Preiß, Prof. Dr. H.-J. Schmoll, Prof. Dr. G. von Minckwitz